Radiopharm Theranostics Limited Sponsored ADR RADX 深 滬
已收盤 08-07 16:00:00 美东时间
2.80
+0.010
+0.36%
華盛通- 最 高2.9248
- 今 開2.90
- 成交量 5.11万股
- 最 低 2.715
- 昨 收 2.79
- 總市值 3307.93万
- 52周最高 16.25
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 2.62
- 委 比 -73.91%
- 總股本 1181.41万
- 歷史最高 50.82
- 量 比 0.69
- 振 幅 7.52%
- 歷史最低 2.62
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, the company raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan. RAD 204 showed promising early clinical signs in a Phase 1 trial, with the fi...
07-31 11:00
Radiopharm Theranostics Sets Target Market for Free Attaching Options
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an announcement. Rad...
07-30 14:48
Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months
Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far
07-22 19:10
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced positive results from its Phase 2b trial of RAD101 for diagnosing suspected recurrent brain metastases. The trial showed 93% concordance between RAD101 PET and MRI imaging, meeting the primary endpoint. Sensitivity was 86% in 14 patients with follow-up data, with specificity results expected in Q4 2026. The company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026. The imaging Brain Metastases ...
07-22 11:00
Radiopharm Secures A$5.9m R&D Tax Refund to Fuel Cancer Radiopharmaceutical Pipeline
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an announcement. Rad...
07-03 13:37
Radiopharm Theranostics Issues New Employee Incentive Options
The latest announcement is out from Radiopharm Theranostics Limited ( ($AU:RAD)...
06-30 14:28
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
On Friday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Lantheus Holdings Inc.’s (NASDAQ:LNTH) New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive neuroendocrine tumors. FDA Issu...
06-29 21:51
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16
HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $16.
06-04 19:15
Radiopharm Theranostics Issues Business Update
Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical
04-23 19:08
